SYRS Projected Dividend Yield
Syros Pharmaceuticals Inc ( NASDAQ : SYRS )Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical stage pipeline of gene control medicines. Co.'s primary product candidates are: Tamibarotene, which is a selective retinoic acid receptor alpha agonist that is being evaluated in combination with azacitidine; SY-2101, which is an oral form of arsenic trioxide; and SY-5609, which is a selective oral inhibitor of cyclin-dependent kinase 7 that is being evaluated in combination with chemotherapy in relapsed/refractory metastatic pancreatic cancer patients. 21 YEAR PERFORMANCE RESULTS |
SYRS Dividend History Detail SYRS Dividend News SYRS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |